anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention discloses application of entacapone to prevention or treatment of obesity and other metabolic syndromes. Specifically, the invention discloses application of entacapone as shown in the formula I or a pharmaceutically acceptable salt thereof to preparation of medicaments for the prevention and / or treatment of metabolic diseases, cardiovascular and cerebrovascular diseases, as well as liver, kidney and thyroid diseases induced therefrom. The metabolic disease is selected from obesity, diabetes and hyperlipidemia; the cardiovascular and cerebrovascular disease is selected from hypertension, coronary heart disease, and atherosclerosis. The prevention and / or treatment of obesity refers to inhibition of body weight increase or promotion of weight loss. The blood lipid is selected from the group consisting of low density lipoprotein, low density lipoprotein-cholesterol, cholesterol and triglyceride. The renal disease is selected from diabetic nephropathy. (img file = &#39;DDA00002485677700011.TIF&#39; wi = &#39;1113&#39; he = &#39;654&#39; /).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new substance for ameliorating anaphylactic type allergic symptoms and to provide a new method for obtaining the new substance.  &lt;P&gt;SOLUTION: A yeast fungus is added to ferment a stevia extract obtained by extraction from a plant tissue of the stevia. In the method, the plant tissue of the stevia is pulverized and mixed and the resultant mixture is introduced into purified water, heated, stirred, cooled and filtered to afford a filtrate. The resultant filtrate is then vacuum concentrated to provide the stevia extract. The yeast fungus is added to ferment the stevia extract.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The invention relates to a traditional Chinese medicine composition for treating coronary heart disease, a preparation method and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 1-10 parts of raw astragalus membranaceus, 1-8 parts of rhizoma polygonati, 1-6 parts of spina date seeds, 0.5-4 parts of honey-fried licorice roots, 0.1-2 parts of pseudo-ginseng powder, 1-8 parts of salvia miltiorrhiza, 0.1-3 parts of dalbergia wood, 0.1-2 parts of cardamom, 1-6 parts of fructus aurantii and 1-6 parts of raw pollen typhae. The invention also comprises a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparing a medicine for treating coronary heart disease. Its advantages are: 1. the traditional Chinese medicine is mainly used for treating the coronary heart disease by tonifying deficiency, simultaneously is used for strengthening middle-jiao and dredging, and can effectively solve the traditional Chinese medicine pathological mechanism of persistent disease of patients with the coronary heart disease, essence and qi deficiency and blood stasis and heart vessel obstruction. 2. The raw material medicaments are preferably selected according to the weight ratio, and the curative effect is good. 3. The raw material medicines accord with the compatibility principle of &#39;monarch, minister, assistant and guide&#39;, the formula is precise, the medicine property is mild, and the compliance of adapted people can be improved.
PURPOSE:To obtain high-purity tetracalcium phosphate in high yield at a low cost by mixing calcium source material powder with phosphorus source material powder at a specific ratio, further blending a specific amount of a boron compound or a mixture thereof with an Al compound therewith and heat-treating the obtained blend at a high temperature. CONSTITUTION:Calcium source material powder (e.g. calcium carbonate powder) is mixed with phosphorus source material powder (e.g. phosphoric acid) so as to provide 2 molar ratio of (Ca/P). A boron compound (e.g. B2O3) in an amount of 0.005-5 pts. based on 100 pts. theoretical amount of produced tetracalcium phosphate expressed in terms of the B2O3 or a mixture of an aluminum compound (e.g.. Al2O3) with the boron compound in the total amount of 0.005-5 pts. expressed in terms of the Al2O3 and B2O3 is further added thereto. The resultant blend is then sintered or melted at &gt;=1400 deg.C temperature to afford the tetracalcium phosphate. A hardened product of the obtained tetracalcium phosphate is useful as materials for artificial bones, dental materials, etc.
The present technology provides a composition for improving brain function. A composition for improving brain function, which comprises acetic acid and/or an acetate salt as an active ingredient. Further, the improvement of brain function is preferably improvement of brain dysfunction or improvement of cognitive dysfunction. Further, the cognitive dysfunction is preferably dementia of the alzheimer&#39;s type or vascular dementia. Further, it is preferably used for oral ingestion. Further, the composition is preferably a food or beverage composition for improving brain function.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tripeptide having a weak adverse reaction and a sex hormone modification action, an eicosapentaenoic acid-bonded tripeptide, furthermore a food preparation, a cosmetic preparation, and a treating agent for endometriosis which contain a sex hormone modification action, have a weak adverse reaction, and are excellent.  &lt;P&gt;SOLUTION: The tripeptide or the extract containing the same and the eicosapentaenoic acid-bonded tripeptide have a sex hormone modification action. The tripeptide used may be either the synthesized or natural substance-derived one. The eicosapentaenoic acid used is collected from fishes or algae. Furthermore, the tripeptide or its extract is obtained by treating egg membranes of the fishes belonging to Gadus, Gadidae, and Clupea with a protease. The protease used is the food processing one. Furthermore, the food preparation, the cosmetic preparation, and the endometriosis treating agent have the tripeptide having a sex hormone modification action as an active ingredient.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention relates to a polysaccharide which is composed of dextrose and uronic acid. The polysaccharide does not contain protein or nucleic acid; the molecular weight is from 1.6*10&lt;6&gt;Da to 2.6*10&lt;6&gt;Da; terminal group carbon is in alpha-conformation; the optical rotation alphaD&lt;t&gt; is from +131.7 degrees to +159.4 degrees. The basic framework of the polysaccharide is composed of dextrose connected by 1 to 4 glucosidic bonds; every 17 dextrose residues share one side chain which is a dextrose molecule or an uronic acid molecule; the proportion of the dextrose to the uronic acid is 2:1, and the dextrose and the uronic acid are both connected with main chain dextrose through 1 to 6 glucosidic bonds; the mass ratio of the dextrose to the uronic acid in each mol of polysaccharide is 53:1. The polysaccharide YCP of the present invention has an obvious inhibiting effect on mouse transplanted tumor Heps and S180. Thus, the polysaccharide YCP of the present invention can be applied to preparing medicines for treating tumors. The present invention also discloses a preparation method of the polysaccharide.
The present invention relates to a medical composite body used for artificial odinopoeia, which is particularly to suitable for the odinopoeia after the pregnant period is longer than 3 months. The composite medicine of the present invention is made by that a medicine admitting unit compositely contains rivanol, antigestagens and prostaglandin, wherein the antigestagens has strong compatible capability with a progesterone receptor and supporting functions for a cell membrane and inhibits the collagen decomposition of the uterus muscle and the uterine neck. The present invention can shorten the odinopoeia time, alleviate the puerpera&#39;s pain and reduce the medical care people&#39;s labor intensity. The composite medicine has the advantages of short time, few pains, safety and reliability from medication to fetal parturition. For the primipara, the average total stage of labor only needs four hours, and the total effective rate is 98%. For the multipara, the labor pains are not obvious from medical medication to the fetal parturition, the average total stage of labor only needs three hours, and the total effective rate is 100%.
In accordance with the principles of the present invention, a method and system of generating food recommendations is provided. A patient drug profile is provided listing currently prescribed medications for a patient. The patient drug profile is analyzed to establish an individual&#39;s medical condition(s), or disease state profile, from National Drug Code numbers, for example, in the patient drug profile. A nutritional database is provided. The nutritional database includes foods that are beneficial and/or harmful to various disease states. Food recommendations based on the individual&#39;s medical condition(s), or disease state profile, are provided from the nutritional database. The food recommendations can include both foods to avoid and foods to consume. Additional information, such as coupons, for example, based on the food recommendations, and a product location guide based on the food recommendations can be provided. In one implementation, the method and system of generating food recommendations can be provided in a pharmacy management system within a grocery store. In another implementation, the method and system of generating food recommendations can be provided using any computing device.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an RNA inhibiting the expression of a Kruppel-like factor 5 (KLF5) gene.  &lt;P&gt;SOLUTION: The RNA comprises a sequence of consecutive 15 to 30 bases of KLF5 mRNA designed from the base sequence of KLF5 cDNA and its complimentary sequence, and inhibits the expression of KLF5 gene. In particular, a double stranded RNA having two uridylic acids added to the 3&#39; end of each of the strands of the double stranded RNA composed of a strand of a specific sequence and a strand of a sequence complementary to the above sequence. The expression of KLF5 gene in a cell can be inhibited by the infusion of the RNA or a vector capable of expressing the RNA into the cell. The RNA or the vector capable of expressing the RNA can be used as a curative medicine for cardiovascular diseases or cancers.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin high in safety, further improved in skin whitening effect, and capable of further improving dull skin, containing a combination of at least one kind of substance selected from L-ascorbic acid derivatives and other six kinds of compounds with an escinol (salt). SOLUTION: This skin preparation for external use contains a combination of at least one kind of substance selected from L-ascorbic acid derivatives, placenta extract, kojic acid and derivatives therefrom, azelaic acid and derivatives therefrom, glucosamine and derivatives therefrom, hydroquinone glycosides and derivatives therefrom and licorice extracts with an escinol (salt) of the formula (R&lt;1&gt; is H or OH; R&lt;2&gt; is a pyranose residue).The contents of the above two kinds of ingredients in the whole amount of the preparation are pref. 0.001-20wt.%, respectively (esp. 0.1-7wt.% for the latter). The L-ascorbic acid derivative is pref. an L-ascorbic phosphoric ester, while the hydroquinone flycoside is pref. as the hydroquinone-α-D-glucose.
NEW MATERIAL:A compound expressed by formula I (R is H, hydroxymethyl or carboxyl; n is an integer 0 or 1), ester and salt thereof. EXAMPLE:beta-( 2,3-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-H-benzopyran-2-y l)alanine hydrochloride. USE:An analgesic agent, having better analgesic action than aspirin with high safety. The agent is administered particularly preferably by oral routes or intravenous injection, and the dose thereof is preferably 100-500mg/day for adults. PREPARATION:An aldehyde expressed by formula II (R&#39; is H or protecting group of OH) is reacted with ammonium carbonate and an alkali metal cyanide, e.g. sodium cyanide, to give a hydantoin expressed by formula III, which is then hydrolyzed to afford the aimed compound expressed by formula I (R is COOH).
Formulations for oral transmucosal compositions that incl ude aromatase inhibitors (Als) in combination with transmucosal absorption enhancers are disclosed. Disclosed oral transmucosal compositions may be for immediate release or slow release, and may be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Disclosed oral transmucosal compositions may incl ude liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms may include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms may be: mucoadhesive liquids such as gel-forming liquid; gel- forming; semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of Als. Disclosed oral transmucosal compositions may allow the delivery of Als directly into the patient&#39;s bloodstream, thus providing high bioavailability of Als; therefore, required dose may be lower. Additionally, adjustments of Als dosages may be achieved when using disclosed oral transmucosal compositions.
The invention describes the expression of a human immunodeficiency virus (HIV) type 1 provirus (F12-HIV) cloned from a nonproducer, chronically-infected CD4 down-regulated Hut-78 cell clone (F12) which does not lead to the formation of viral particles and, upon transfection in HeLa CD4+ cells, confers resistance to HIV superinfection without affecting CD4 receptor exposure. A Moloney murine leukemia virus-based retroviral vector containing an F12-HIV genome lacking the 3&#39; long terminal repeat (LTR) and part of the nef gene, expressed under the control of its 5&#39; LTR, was constructed to facilitate the transfer of the anti-HIV properties of F12-HIV into human cells. The F12-HIV genome was inserted in an orientation opposite to that of the murine leukemia virus transcriptional unit and was designated the N2/F12-HIV nef- antisense vector. Lymphoblastoid CEMss cells, as well as human peripheral blood lymphocytes, were successfully transduced by the recombinant retrovirus. CEMss clones expressing the F12-HIV nef- antisense vector were resistant to HIV superinfection even at the highest multiplicity of infection tested (105 50% tissue culture infective doses per 106 cells). Nonproducer, interfering HIV proviruses transduced into retroviral vectors may provide an alternative strategy for the protection of CD4+ human primary cells from HIV infection.
Preparation of N-dialkylamino- or N-heterocyclic-substituted maleic or isomaleic imides by reacting a maleic acid monohydrazide of the formula &lt;FORM:1116173/C2/1&gt; where R1 and R2 each represents an alkyl group or together with the nitrogen atom to which they are attached form a heterocyclic ring optionally containing a further hetero atom, in a solvent at a temperature from - 10 DEG  to + 50 DEG  C., with an amido-chloride derived from a carboxylic acid.  The amido-chloride is preferably prepared from an N,N-disubstituted carboxylic acid amide particularly a N,N-dialkyl-substituted formamide, e.g. dimethylformamide, by the action of an inorganic acid chloride such as thionyl chloride, phosgene, phosphorous oxychloride or phosphorus pentachloride and is not purified prior to use.  The reaction may be carried out in an N,N-disubstituted carboxylic acid amide solvent preferably the amide from which the amido-chloride is derived.  The preparation of N-dimethylamino-and N-morpholyl-maleic imide and N-tetrahydrothiazinylisomaleic imide dioxide is described.ALSO:Anti - microbial N - (di - substituted - amino) - maleic imides are obtained by reacting a compound of the formula:  &lt;FORM:1116173/A5-A6/1&gt; wherein R1 and R2 each represent an alkyl group with an amido chloride derived from a carboxylic acid.  In particular, N - dimethylamino - maleic imide is totally germicidal when added 1:4000 to innoculated optimum nutrient solutions of Bacterium coli, Pseudomonas pyocyanea, Bacillus subtilis, Trichophyton mentagrophytes and Saccaromyces.
A material which is capable of lowering platelet count or fibrinogen concn. or both is isolated from spleen by extracting with a polar solvent of dielectric constant of &gt;=20 and then chromatographing the resulting soln. either by silica gel t.l.c. eluting with benzene or by glass column chromatography eluting with benzene or methanol. The material has an Rf value of 0-0.73 and a m.pt. is not &gt;70 degrees C. The material is soluble in acetone, benzene and ether and can be extracted by these solvents. It can be separated into fractions TLC1, TLC 2A, TLC 2B and TLC 3. TLC1 and the dyes butter yellow sudan red 6 and indophenol blue when subjected to a 250 micron thick Analtech silica gel G.F plate using a benzene eluting solvent have Rf values of 0.66, 0.40, 0.17 and 0.05 respectively.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop a new material for preventing hands/feet and/or face dropsy symptoms and dropsy feeling which are developed spontaneously in daily life, and to provide a dropsy-preventive agent and an oral composition each using the above new material.  &lt;P&gt;SOLUTION: The dropsy-preventive agent comprises, as an active ingredient, a plant belonging to the genus Astilbe such as Astilbe thunbergii (SIEB. et ZUCC.) Miq., more preferably its extract obtained by extraction of the plant with water and/or a hydrophilic organic solvent. The oral composition containing the above dropsy-preventive agent is also provided. Besides, a method for preventing dropsy characterized by comprising orally administering the plant or its extract is provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a process and an apparatus by which a hydrogen-containing biocompatible solution to be used for injection, drip, infusion, organ preservation, etc. is easily produced.  &lt;P&gt;SOLUTION: A biocompatible solution enclosed in a container 2i such as an infusion (drip) bag having hydrogen permeability. The biocompatible solution together with the container is placed in another container 2g having a size large enough to accommodate it. A liquid or a gas containing hydrogen molecules (hereafter, hydrogen storage container) is fed to the container 2g. Hydrogen molecules are included in the biocompatible solution by bringing it in contact with hydrogen molecules from outside of the container.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
FIELD: medicine. ^ SUBSTANCE: group of invention belongs to versions of pharmacologic composition designed for stimulation of cells&#39; growth and regeneration and to methods of composition&#39;s manufacture. Composition contains lysate of peripheral blood leukocytes, stem and progenitor cells obtained from animal which preliminary undergone biopsy of those inner organs or skin, in which growth and regeneration must be stimulated. Another version of composition contains lysate of peripheral blood leucocites and/or stem and/or progenitor cells obtained from animal which preliminary undergone biopsy of those inner organs or skin, in which growth and regeneration must be stimulated. Peripheral blood leukocytes and/or stem and/or progenitor cells was preliminary cultivated with obtained by biopsy destroyed cells of inner organs or skin in which growth and regeneration must be stimulated. Versions of manufacture method include cells&#39; acquisition followed by destruction. ^ EFFECT: invention provides improvement of regeneration process in affected organ. ^ 14 cl, 2 tbl, 6 dwg, 7 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a permanent magnet keeper-shield assembly.  &lt;P&gt;SOLUTION: The magnet keeper-shield assembly adapted to hold and preserve a permanent magnet used for generating a high-gradient magnetic field. Such magnetic field can be penetrated into a deep target tumor area in order to attract a magnetically responsive microcarrier. The magnet keeper-shield assembly includes a magnetically transparent keeper-shield having bores dimensioned to hold the magnet. A screw power transmission actuator is used to partially extrude the magnet from the keeper-shield. This actuator is assisted by several springs extended through the base portion of the keeper-shield.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
The invention discloses a kind of pair of branch type shampoo pattern, it is characterised in that including：No. 1 agent and No. 2 agent；The operating procedure of No. 1 agent and No. 2 agent is as follows：First by person scalp is sent to No. 1 agent cleaning head once, and it is clean to wash by water；Then user is sent to scalp once with No. 2 agent hair washing, and rinses well.A kind of pair of branch type shampoo pattern disclosed by the invention, it is No. 1 agent by different formulations and the matched combined of No. 2 agent, same area can wash twice of custom when being washed hair using people, tradition is repeated twice hair washing with single shampoo it is changed into different purposes and has one&#39;s hair wash twice, it is not only easy to use, and hair washing function is more precisely reliable, is the upgrading and breakthrough of traditional hair washing product, tradition clean type can be achieved to accurate health convalescence type to upgrade, there are wide market prospects.
&lt;P&gt;PROBLEM TO BE SOLVED: To overcome prior art defects and other defects by providing a new radiolabeling strategy for targeting the tissue for imaging.  &lt;P&gt;SOLUTION: A radiolabeled tissue-specific ligand, a method for preparing this radiolabeled ligand, a method of using this radiolabeled ligand for imaging tissue-specific diseases, and a composition for imaging tissue-specific diseases are provided. This imaging composition typically comprises ethylenedicysteine and a radionuclide label which is conjugated to the ethylenedicysteine on one or both acid arms and is chelated with a tissue-specific ligand. This ethylenedicysteine forms an N&lt;SB&gt;2&lt;/SB&gt;S&lt;SB&gt;2&lt;/SB&gt;chelate having the radionuclide label. Naturally, this chelate compound contains an ionic bond between the radionuclide and the chelate compound.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an antitumor agent given by using a composite Chinese herbal medicine scarcely having side effects.  &lt;P&gt;SOLUTION: The antitumor agent is obtained by deacetylating various kinds of mushrooms, including ganoderma and agaricus, as raw materials, deoxygenating the deacetylated materials to form calcium β-glucan, making the calcium β-glucan easily soluble, mixing the Chinese herbal medicine, including ganoderma spawn, therewith, and further adding notoginseng radix, glycyrrhizin, tannic acid, monordicae fructus juice, saponin, or the like, thereto. A tungstate salt or a molybdate salt having bacteriostatic and fungistatic effects on bacteria, fungi, and viruses, or Adenophora pereskiaefolia is further added to the agent. Thus, the agent is effective for treating maxillary/submaxillary cancer, laryngeal cancer, lingual cancer, and uterine cancer which are conventionally not treated by single administration of the ganoderma or the agaricus, and has an immediate effect, when the Adenophora pereskiaefolia is together used. Therefore, the agent is effective for treating the cancers, without surgically treating the cancers.  &lt;P&gt;COPYRIGHT: (C)2004,JPO